Abstract:Introduction: Using the Plectin1-targeting self-assembled peptide nanoparticle (PTNP) encapsulated with BET inhibitor JQ1 and PARP inhibitor Olaparib (Ola) to target accurately and suppress non-BRCA mutant pancreatic ductal adenocarcinoma (PDAC) synergistically Method: The morphologies of self-assembled peptide nanoparticle and drug-loaded nanoparticle were assessed by transmission electron microscopy (TEM); the entrapment efficiency of nanoparticles was analyzed by high performance liquid chromatography (HPLC); the drug release profiles of drug-loaded nanoparticle in vitro was evaluated by dialysis method; the targeting ability of nanoparticles was measured by flow cytometry and laser confocal microscopy; the synergetic effect was measured by western blot and flow cytometry. The in vivo stability and tumor targeting capability of peptide nanoparticle were determined by in vivo imaging system. The in vivo therapeutic effect was verified by orthotopic PDAC model. Result: The Plectin1-targeting self-assembled peptide could rapidly self-assemble into spherical nanoparticles. The diameter of PTNP was about 20 nm, and it turned to 50 nm after drug loading. After incubation for 48 hours in 10% serum solution, the morphology of drug-loaded nanoparticles PTNP-JQ1-Ola showed no obviously change, indicating that its structure was relatively stable. The entrapment efficiencies of JQ1 and Ola were both about 70%. The results of flow cytometry and laser confocal microscopy manifested that PTNP targeted Plectin1-overexpressed PDAC cells effectively. The western blot analysis indicated that PTNP loading JQ1 combined with Ola synergistically induced DNA damage and this nano-drug system resulted in higher apoptosis rate. The result of in vivo imaging system showed that PTNP had stronger accumulation in tumor site indicating the positive targeting effect of the nanoparticles on plectin1-overexpressed tumor. The PTNP-JQ1-Ola system had stronger inhibition on PDAC growth in orthotopic model. Conclusion: The plectin1-targeting self-assembled peptide nanoparticle loading with JQ1 and Ola targets PDAC effectively and thus improving the synthetic lethality capacity on non-BRCA mutant PDAC.

Synthetic Lethality in non-BRCA Mutant PDAC with Codelivery JQ1 and Olaparib via a Plectin1 Targeting Peptide Nanoparticle

Trap and Kill Strategy for Non-Brca Mutant Pancreatic Cancer by Co-Delivery of Olaparib and JQ1 with Plectin-1 Targeting Peptide Nanoparticles

Enhancement of Antitumor Efficacy of Paclitaxel-Loaded PEGylated Liposomes by N,N-Dimethyl Tertiary Amino Moiety in Pancreatic Cancer

Synergistic Antitumor Efficacy of Rmv-Hu191 and Olaparib in Pancreatic Cancer by Generating Oxidative DNA Damage and ROS-dependent Apoptosis

Plectin-1-targeted recognition for enhancing comprehensive therapy in pancreatic ductal adenocarcinoma

Epidermal Growth Factor Receptor Targeting Peptide Nanoparticles Simultaneously Deliver Gemcitabine and Olaparib to Treat Pancreatic Cancer with Breast Cancer 2 (BRCA2) Mutation

Terminating the Criminal Collaboration in Pancreatic Cancer: Nanoparticle-based Synergistic Therapy for Overcoming Fibroblast-Induced Drug Resistance

PD-1/PD-L1 Pathway and Angiogenesis Dual Recognizable Nanoparticles for Enhancing Chemotherapy of Malignant Cancer

Codelivery of Doxorubicin/PI3K Inhibitor Nanomicelle Linked with Phenylboronic Acid for Enhanced Cytotoxicity to Pancreatic Cancer

Enhanced cisplatin chemotherapy sensitivity by self-assembled nanoparticles with Olaparib

Use of ratiometrically designed nanocarrier targeting CDK4/6 and autophagy pathways for effective pancreatic cancer treatment

A Nano-targeted Co-delivery System Based on Gene Regulation and Molecular Blocking Strategy for Synergistic Enhancement of Platinum Chemotherapy Sensitivity in Ovarian Cancer

Nanoparticulate drug combination inhibits DNA damage repair and PD-L1 expression in BRCA-mutant and wild type triple-negative breast cancer

KP372-1-Induced AKT Hyperactivation Blocks DNA Repair to Synergize With PARP Inhibitor Rucaparib via Inhibiting FOXO3a/GADD45α Pathway

Synergistic Therapy for Cervical Cancer by Codelivery of Cisplatin and JQ1 Inhibiting Plk1-Mutant Trp53 Axis

A Self‐Assembly Combined Nano‐Prodrug to Overcome Gemcitabine Chemo‐Resistance of Pancreatic Tumors

Polymeric Nanomedicine for Combined Gene/Chemotherapy Elicits Enhanced Tumor Suppression

Reprogramming the pancreatic cancer stroma and immune landscape by a silicasome nanocarrier delivering nintedanib, a protein tyrosine kinase inhibitor

Anti-PD-L1 peptide-conjugated prodrug nanoparticles for targeted cancer immunotherapy combining PD-L1 blockade with immunogenic cell death

Co-inhibition of the TGF-β Pathway and the PD-L1 Checkpoint by Ph-Responsive Clustered Nanoparticles for Pancreatic Cancer Microenvironment Regulation and Anti-Tumor Immunotherapy.

Β-Lapachone and Paclitaxel Combination Micelles with Improved Drug Encapsulation and Therapeutic Synergy As Novel Nanotherapeutics for NQO1-Targeted Cancer Therapy.